New Delhi, Aug 10: The government has approved Biological E’s Corbevax as a booster dose or precaution dose for adults above18 who have had both the Covishield and Covaxin vaccines.
This is the first time a different booster dose than the one used for the primary Covid vaccination has been authorised in the nation.
According to the sources cited by Press Trust of India, the recent recommendations provided by the COVID-19 Working Group of the National Technical Advisory Group on Immunization served as the foundation for the Union Health Ministry’s acceptance (NTAGI).
According to the sources, this will be in addition to the current recommendations for administering homologous prophylactic doses of the Covaxin and Covishield vaccines. On the Co-WIN portal, all essential adjustments are being made in relation to the delivery of the precautionary dosage of the Corbevax vaccination.
Corbevax, the country’s first RBD protein subunit vaccine, is presently administered to youngsters between the ages of 12 and 14 as part of the COVID-19 immunisation programme.
In its meeting on July 20, the COVID-19 Working Group (CWG) reviewed data from the double-blind randomised phase-3 clinical study that assessed the immunogenicity and safety of a booster dose of the Corbevax vaccine when given to adult volunteers aged 18 to 80 who had previously received two doses of either Covishield or Covaxin.
On June 4, the Drugs Controller General of India (DCGI) approved Corbevax as a precautionary dose for individuals 18 years of age and above. Indian healthcare and frontline workers, as well as the people above 60 years, started receiving precautionary vaccination doses from January 10. On April 10, India started giving COVID-19 booster doses or prophylactic doses to all adults over the age of 18.